Enlonstobart Biosimilar – Anti-Programmed cell death protein 1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1943; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Enlonstobart Biosimilar is a novel therapeutic antibody that targets the programmed cell death protein 1 (PD-1) pathway. This biosimilar is a highly specific and potent anti-PD-1 monoclonal antibody (mAb) that has been developed for the treatment of various types of cancer. In this article, we will provide a scientific description of the structure, activity, and potential applications of Enlonstobart Biosimilar.
Enlonstobart Biosimilar is a recombinant humanized IgG4 monoclonal antibody that has been designed to mimic the structure and function of the naturally occurring PD-1 antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Enlonstobart Biosimilar is responsible for its high specificity and binding affinity to the PD-1 receptor.
Enlonstobart Biosimilar works by binding to the PD-1 receptor on the surface of T cells and blocking its interaction with its ligands, PD-L1 and PD-L2. This prevents the inhibitory signals that are normally transmitted through the PD-1 pathway, allowing the T cells to become activated and mount an immune response against cancer cells. This mechanism of action makes Enlonstobart Biosimilar a promising therapeutic agent for the treatment of cancer.
Enlonstobart Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It has also shown potential for use in combination with other cancer therapies, such as chemotherapy and radiation therapy.
cancer that is known to be highly resistant to conventional treatments. However, studies have shown that the PD-1 pathway plays a critical role in the development and progression of melanoma. Enlonstobart Biosimilar has shown promising results in clinical trials for the treatment of advanced melanoma, both as a monotherapy and in combination with other therapies.
cancer and is known to be highly aggressive and difficult to treat. Enlonstobart Biosimilar has shown promising results in clinical trials for the treatment of advanced NSCLC, particularly in patients who have failed previous treatments. It has also shown potential for use in combination with other therapies, such as chemotherapy and targeted therapy.
cancer that is known to be resistant to conventional treatments. Enlonstobart Biosimilar has shown promising results in clinical trials for the treatment of advanced RCC, both as a monotherapy and in combination with other therapies. It has also shown potential for use in combination with other immunotherapies, such as anti-CTLA-4 antibodies.
Enlonstobart Biosimilar is a novel anti-PD-1 monoclonal antibody with a highly specific and potent mechanism of action. Its promising results in preclinical and clinical studies make it a potential game-changer in the treatment of various types of cancer. With ongoing research and development, Enlonstobart Biosimilar has the potential to become a valuable addition to the arsenal of cancer therapies.
ProteoGenix catalogue number PX-TA1943. For research use only.
Target: Enlonstobart Biosimilar – Anti-Programmed cell death protein 1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Enlonstobart Biosimilar – Anti-Programmed cell death protein 1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
